Allergan Plc (AGN) 336.64 $AGN
What to Watch Thursday -- Trump, Bush, Allergan Earnings, Jobless Claims
at The Street - Wed Aug 05, 7:15PM CDT
On Thursday August 6, TheStreet will be covering the first Republican Presidential debates, earnings from drug manufacturer Allergan and media company Viacom, and jobless claims.
AGN: 336.64 (+5.64), PBR: 6.32 (-0.13), MNST: 154.00 (+2.28), DUK: 73.98 (+0.06), LGF: 37.42 (-1.36), KYTH: 74.72 (+0.17), TEVA: 71.19 (+0.50), VIAB: 51.41 (-4.19)
Sucampo hits high on EPS
at Investor's Business Daily - Wed Aug 05, 5:43PM CDT
The specialty drugmaker's Q2 EPS was 21 cents up from 4 cents a year ago, beating views by 6 cents. Revenue grew 45% to $34.9 mil, above views. Sucampo (SCMP) raised its full-year EPS guidance to 65-75 cents, above analysts' views for 62 cents. But a...
AGN: 336.64 (+5.64), SCMP: 22.24 (+0.66), CVS: 111.20 (+1.24)
Third Point buys stake in Baxter, wants to help pick new CEO
AP - Wed Aug 05, 3:37PM CDT
NEW YORK (AP) — Hedge fund Third Point has become the biggest shareholder in Baxter International and wants to help choose the medical products maker's next CEO.
AGN: 336.64 (+5.64), BAX: 42.13 (+1.82), AMGN: 176.44 (+1.64), DOW: 47.13 (+0.44)
FDA Approves 28 Additional Styles Of Allergan's Natrelle® 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants
PR Newswire - Wed Aug 05, 3:26PM CDT
Allergan, plc. (NYSE: AGN) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market 28 additional styles of Natrelle® 410 silicone-filled breast implants, giving surgeons and patients more options to achieve desired outcomes. The FDA approved extra-full projection styles (X), along with additional low projection, low height styles (L) from the Natrelle® 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implant line, for use in breast reconstruction, augmentation and revision surgery.
AGN: 336.64 (+5.64)
Allergan (AGN) Stock Climbs Ahead of Second Quarter Results
at The Street - Wed Aug 05, 2:59PM CDT
Allergan (AGN) shares are rising ahead of the release of its second quarter financial results tomorrow morning before the opening bell.
AGN: 336.64 (+5.64)
What Company Will Be Fastest Growing Big-Cap Biotech?
at Investor's Business Daily - Wed Aug 05, 1:58PM CDT
While drugs for treating and curing hepatitis C have made one biotech company the envy of the industry, another biotech -- Celgene -- is poised to break ahead of its peer pack over the next few years. Celgene's (CELG) sales and profit growth is seen...
AGN: 336.64 (+5.64), BIIB: 335.41 (+5.03), GEVA: 238.60 (+2.80), PCYC: 261.25 (+1.70), GILD: 118.66 (-0.21), AZN: 34.54 (+0.20), ALXN: 197.94 (+0.79), RCPT: 228.97 (+0.97), AMGN: 176.44 (+1.64), ABBV: 70.30 (+0.35), JUNO: 46.67 (+0.17), CELG: 132.72 (+1.64)
Jim Cramer Is Watching Allergan's Earnings After Generics Sale to Teva
at The Street - Wed Aug 05, 1:50PM CDT
Allergan is set to report earnings on Thursday, before the markets open, and Jim Cramer is keeping a sharp eye on its results.
AGN: 336.64 (+5.64), VRX: 262.52 (+2.54)
Sucampo Stock Hits High On EPS, But CVS Nixes Drug
at Investor's Business Daily - Wed Aug 05, 11:52AM CDT
Specialty drugmaker Sucampo Pharmaceuticals (SCMP) beat Q2 expectations and raised its guidance early Wednesday, sending the stock to a new high in early trading. It pulled back later, however, possibly because word got out that its sole marketed...
AGN: 336.64 (+5.64), SCMP: 22.24 (+0.66), MYL: 54.60 (-0.07), CVS: 111.20 (+1.24)
Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023
M2 - Wed Aug 05, 10:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7x2jmw/antibacterial) has announced the addition of the "Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023" report to their offering. "Antibacterial Drugs Market (By Class - Aminoglycosides, B-Lactams, Tetracyclines, Sulfonamides, Quinolones/ Fluoroquinolones, Macrolides, Phenicols and Miscellaneous Antibacterials, and Pipeline Drugs) - 2015 - 2023 This report on antibacterial drugs market studies the current as well as future prospects of the market globally. The market for antibacterial drugs is segmented on the basis of major classes of drugs,namely,aminoglycosides,B-lactams, tetracyclines, sulfonamides, quinolones/fluoroquinolones, macrolides, phenicols and miscellaneous antibacterials. The market for each of these classes has been extensively analyzed on the basis of leading drug launch, patent expiry, drug efficacy, annual sales revenue and geography wise regulatory approval. The market size and forecast in terms of USD million for each of these classes has been provided for the period 2013 to 2023, considering 2013 and 2014 as the historical and base year respectively, while the market forecast has been provided for the period 2015 to 2023. Geographically, the antibacterial drugs market has been categorized into five regions, namely, North America, Europe, Asia Pacific, Latin America and Rest of the World (ROW). Each of these geographies have been further segmented with respect to major countries; where North America is segmented in U.S. and Canada, Europe is segmented in U.K., Germany and rest of Europe, Asia Pacific is segmented in China, Japan and rest of Asia Pacific, and Latin America is segmented in Brazil and rest of Latin America. Companies Mentioned - AstraZeneca plc - Allergan plc (Actavis Plc) - Bayer AG - Bristol-Myers Squibb Company - Eli Lilly and Company - GlaxoSmithKline plc - Johnson & Johnson - Merck & Co., Inc. - Novartis AG - Pfizer, Inc. - Sanofi Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Antibacterial Drugs Market Revenue, by Class, 2013 - 2023 (USD Million) Chapter 5 Global Antibacterial Drug Pipeline Analysis Chapter 6 Global Antibacterial Drugs Market Revenue, by Geography, 2013 - 2023 (USD Million) Chapter 7 Recommendations Chapter 8 Company Profiles For more information visit http://www.researchandmarkets.com/research/7x...ibacterial
AGN: 336.64 (+5.64), JNJ: 100.52 (+0.72), PFE: 35.82 (-0.29), MRK: 59.10 (+0.40), AZN: 34.54 (+0.20), LLY: 84.73 (+0.68), GSK: 44.17 (+0.72), BMY: 65.06 (+0.22), NVS: 103.25 (-0.32)
Sustained Release Ocular Drug Delivery Systems, 2015 - 2025
M2 - Wed Aug 05, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g2gzr3/sustained_release) has announced the addition of the "Sustained Release Ocular Drug Delivery Systems, 2015 - 2025 (2nd edition)" report to their offering. The Sustained Release Ocular Drug Delivery Systems, 2015 - 2025 (2nd edition)' report provides an extensive study of the emerging market of implants and particulate drug delivery systems (DDS) for ophthalmic diseases. The focus of this study is on commercial implants and those under development, their applications and the likely mid-term and long-term evolution. It is widely anticipated that such drug delivery systems have tremendous potential as they provide improved retention time compared to topical applications and offer convenience over regular intravitreal injections, mainly for posterior eye diseases. The report covers various aspects such as technological progress, product pipeline, target indications, industry and academic research programs to assess new evolving opportunities. We have provided a competitive spider web analysis to compare different implants based on technical parameters (drug elution rate, amount of drug delivered, life of implant etc.) and their likely user friendliness. Our opinion and insights, presented in this study, were influenced by the discussions that we conducted with different ophthalmic implant developers in this industry. The base year for the report is 2014. The report provides market forecasts for the following two time horizons: 2015 - 2020 and 2020 - 2025. In addition to the above, we have also provided our own independent perspective on the key drivers behind the growth of this market, likely challenges and potential threats. The research, analysis and insights presented in this report include the sales potential of various marketed and late stage pipeline ocular sustained drug delivery systemsbased on the current expected launch timelines, adoption rates and the estimated end-use price points.The figures mentioned in this report are in USD, unless otherwise specified. Highlights: - More than 25 companies are currently working on developing sustained release drug delivery systems for the treatment of ocular indications. Examples of some key players include pSivida, Allergan, Ocular Therapeutix, Neurotech Pharmaceuticals, Icon BioScience and GrayBug. - Vitrasert, launched in 1996, was the first ocular implant. It was, however, taken off the market in 2013. Only three more implants have received regulatory approval since 1996; these are Retisert, Ozurdex and Iluvien. - Majority of the systems (52%) are in preclinical stage of development. Over 10 systems are currently undergoing late stage clinical trial studies. Once approved, these inserts are likely to provide a major impetus to the overall market. - DME and Uveitis will provide the much needed boost to the sustained release ocular drug delivery systems market in the short-term. In the mid to long term, the growth will be fostered by launch of sustained release systems for glaucoma and AMD. In fact, more than 15 sustained release formulations are under development for the treatment of glaucoma. - Interest of venture capital firms, licensing/ partnership opportunities will continue to act as key growth drivers of this market. During our research, we identified several instances where venture capitalists and other strategic investors have actively supported the research efforts. - The overall market is likely to be more than USD 6.5 billion in the coming decade. The opportunity could be much higher in the outer years, especially driven by the regulatory approval of implants for delivery of biologics. Key Topics Covered: 1. Preface 2. Executive Summary 3. Introduction 4. Market Overview 5. Product Profiles and Sales Forecast 6. Company Profiles 7. Venture Capital Support 8. Recent Partnerships 9. SWOT Analysis 10. Interview Transcripts 11. Conclusion 12. Appendix 1: Tabulated Data 13. Appendix 2: List Of Companies Companies Mentioned - Partial List of Companies - 3i Plc - AbbVie - Abell Foundation - Aciont, Inc. - Actavis Plc - Aerie Pharmaceutical - Ain Shams University, Cairo, Egypt - Alcon - Alimera Sciences - Allergan - Alliance Medical Products Inc - Alpha Associates - Amgen Inc. - Amorphex Therapeutics - Apax Partners - Ascension Health Ventures - Atlas Venture - Auritec Pharmaceuticals - Avida Group - Bausch & Lomb - Baxter Venture - Bayer Healthcare - BCN Peptides - Ben Venue Laboratories - BioLight Israeli Life Sciences Investments Ltd. - Brandon Biosciences - Brecon Pharmaceuticals Ltd - Brown Advisory For more information visit http://www.researchandmarkets.com/research/g2...ed_release
AGN: 336.64 (+5.64), ALIM: 4.69 (-0.10), AMGN: 176.44 (+1.64), OCUL: 23.43 (+1.38)
Ironwood and Allergan Enter Agreement to Co-Promote VIBERZI for Irritable Bowel Syndrome with Diarrhea (IBS-D) in the U.S.
Business Wire - Wed Aug 05, 8:25AM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today an agreement with Allergan plc for the U.S. co-promotion of VIBERZI(TM) (eluxadoline), Allergan's new treatment for adults suffering from irritable bowel syndrome with diarrhea (IBS-D). This arrangement is separate from and complementary to the companies' ongoing co-development and co-commercialization of LINZESS(R) (linaclotide) for the treatment of adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).
AGN: 336.64 (+5.64), IRWD: 10.72 (+0.10)
Pharmaceuticals Partnerships, Licensing, Investments and M&A Deals and Trends for 2014
M2 - Wed Aug 05, 7:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qkmkxx/partnerships) has announced the addition of the "Partnerships, Licensing, Investments and M&A Deals and Trends for 2014 in Pharmaceuticals" report to their offering. Partnerships, Licensing, Investments and M&A Deals and Trends for 2014 in Pharmaceuticals report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in 2014. The report portrays detailed comparative data on the number of deals and their value in the last five years, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry. Major Highlights - Actavis Acquires Allergan for USD70.5 Billion - Medtronic Acquires Covidien for USD49.9 Billion - Actavis Completes Acquisition of Forest Labs for USD28 Billion - Sigma-Aldrich Receives Antitrust Approval for its Acquisition by Merck for USD17 Billion - Novartis Acquires Cancer Drugs Business of GlaxoSmithKline - Bayer Acquires Consumer Healthcare Business of Merck for USD14.2 Billion - GlaxoSmithKline Acquires Consumer Healthcare Pharma Business of Novartis - Merck Acquires Cubist Pharma for USD9.5 Billion - McKesson Completes Acquisition Of Celesio For US$8.49 Billion - Roche Completes Tender Offer to Acquire InterMune for USD8.3 Billion Key Topics Covered: 1 Tables & Figures 2 Pharmaceutical & Healthcare, Global, Deals Summary 3 Pharmaceuticals & Healthcare, Global, Top Deal Makers, 2014 4 Pharmaceuticals & Healthcare, Global, Deal Summary, by Type 5 Pharmaceuticals & Healthcare, Global, Deal Summary, By Market 6 Pharmaceuticals & Healthcare, Deal Summary, By Geography 7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 8 Further Information For more information visit http://www.researchandmarkets.com/research/qk...rtnerships
AGN: 336.64 (+5.64), MDT: 78.67 (+0.90), MRK: 59.10 (+0.40), GSK: 44.17 (+0.72), NVS: 103.25 (-0.32)
Allergan and KYTHERA Announce That Pending Transaction Will Now be for All-Cash Consideration
GlobeNewswire - Wed Aug 05, 7:00AM CDT
Allergan plc (NYSE:AGN) and KYTHERA Biopharmaceuticals, Inc. (NASDAQ:KYTH) today announced that they have amended and restated their merger agreement with respect to Allergan's pending acquisition of KYTHERA to provide for all-cash consideration to KYTHERA's stockholders. The agreement amends and restates the original merger agreement entered into by the parties on June 17, 2015, as amended on July 1, 2015.
AGN: 336.64 (+5.64), KYTH: 74.72 (+0.17)
Allergan and KYTHERA Announce that Pending Transaction will now be for All-Cash Consideration
PR Newswire - Wed Aug 05, 7:00AM CDT
Allergan plc (NYSE: AGN) and KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that they have amended and restated their merger agreement with respect to Allergan's pending acquisition of KYTHERA to provide for all-cash consideration to KYTHERA's stockholders. The agreement amends and restates the original merger agreement entered into by the parties on June 17, 2015, as amended on July 1, 2015.
AGN: 336.64 (+5.64), KYTH: 74.72 (+0.17)
Top Mutual Funds Pile In Celgene Other Leading Stocks
at Investor's Business Daily - Tue Aug 04, 5:51PM CDT
IBD's new buys list showed the country's leading stock mutual funds the past three months have continued to gobble up top-rated medical stocks, such as Allergan (AGN), Celgene (CELG), Regeneron Pharmaceuticals (REGN), Molina Healthcare (MOH) and...
ACHC: 82.97 (+5.08), LAD: 119.80 (+0.81), MNST: 154.00 (+2.28), NKE: 116.75 (+0.98), SKX: 160.29 (+6.39), ORLY: 244.17 (+0.80), VFC: 76.72 (+0.49), GOOG: 643.78 (+14.53), MOH: 77.24 (+1.84), CELG: 132.72 (+1.64), SBUX: 59.01 (+0.31), AGN: 336.64 (+5.64), TSS: 47.54 (+0.47), PZZA: 71.45 (-4.16), HAWK: 45.45 (-0.14), ULTA: 167.01 (+1.94), REGN: 592.40 (+11.46)
Akorn's
at Investor's Business Daily - Tue Aug 04, 5:41PM CDT
Akorn's (AKRX) Hi-Tech Pharmacal lost after when the U.S. Court of Appeals for the Federal Circuit ruled that Akorn had infringed on 3 Allergan (AGN) patents for its Lumigan topical glaucoma treatment, Reuters reported. Akorn shares fell 0.7% to...
AGN: 336.64 (+5.64), AKRX: 45.12 (-0.74)
Will Allergan's (AGN) Earnings Streak Continue in 2Q? - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Aug 04, 5:02PM CDT
Allergan's (AGN) top as well as bottom line should continue to be driven by the acquisition of Botox-maker Allergan Inc. as well as other acquisitions.
BDSI: 7.81 (+0.17), DVAX: 29.73 (-0.48), AGN: 336.64 (+5.64), TEVA: 71.19 (+0.50)
Asia, Europe, and South America Anti-aging Market - Industry Analysis 2014 - 2020
M2 - Tue Aug 04, 8:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lsx3v/asia_europe_and) has announced the addition of the "Asia, Europe, and South America Anti-aging Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020" report to their offering. The anti-wrinkle products segment was valued at USD 8,088.3 million in 2013 in Asia The dominance of this segment was primarily due to increasing adoption of anti-wrinkle products among the population. The anti-aging products market in Japan is growing swiftly owing to reasonable costs and rising awareness about the availability of aesthetic products. According to the International Society of Aesthetic Plastic Surgeons (ISAPS), a total of 146,150 Botox injection procedures were registered in Japan in 2010. The number further increased to 208,313 in 2011. Considering all the above mentioned factors, Japan was leading the overall anti-aging products market in Asia in terms of revenue in 2013. While on the other hand, China is expected to show significant growth in the anti-aging products market during the forecast period. Factors such as anticipated rise in the aging population coupled with rising awareness about commercially available anti-aging products are primarily driving the growth of the market in China. The anti-aging services market is growing rapidly in Europe owing to steady recovery from the economic crisis, and consequently, rising disposable income and increasing demand. Italy was a leader in the anti-aging services market in the overall Europe in 2013 due to higher demand for breast augmentation and hair restoration treatments. While on the other hand, Spain anti-aging services market is expected to record highest growth during the forecast period. Adoption of sclerotherapy is anticipated to primarily boost the growth of the Spain anti-aging treatment services market owing to the increasing prevalence of varicose vein due to aging and obesity. The growth of the geriatric population coupled with rise in obesity are some of the other factors driving the growth of sclerotherapy services segment in the country. Brazil dominates the aesthetic procedures industry among South American countries. Brazil registered 1,447,213 aesthetic procedures in 2011. Affordable rates, availability of advanced techniques and a well-defined regulatory infrastructure are the prime drivers for the growth of the aesthetic industry in Brazil. As a result, people around the world travel to Brazil for aesthetic treatment. Thus, increasing demand for aesthetic procedures in the country is observed that would boost the growth of aesthetic devices in Brazil. Similarly, adoption of laser treatment and radiofrequency treatments is observed to be higher in Brazil owing to the safety and efficacy of these treatments. Therefore, in 2013, the laser aesthetic and radiofrequency devices segments accounted for the largest market of USD 59.0 million and USD 19.2 million, respectively. Some of the key players operating in the anti-aging market include Allergan, Inc., Alma Laser Ltd., Beiersdorf AG, Coty, Inc., Cynosure, Inc., L'Or?al SA, Solta Medical, Inc. (Valeant Pharmaceutical International, Inc.), and PhotoMedex, Inc. For more information visit http://www.researchandmarkets.com/research/4l...europe_and
AGN: 336.64 (+5.64), CYNO: 39.67 (+0.59), COTY: 28.32 (+0.83)
5 Top Medical Stocks Reporting Earnings This Week
at Investor's Business Daily - Mon Aug 03, 12:05PM CDT
Before Wall Street escapes for summer vacation, makers of drugs and medical devices are greeting August with a frantic week of earnings reports. Here are five of the leading stocks reporting this week: On Tuesday morning, big biotech Regeneron...
AGN: 336.64 (+5.64), MNK: 104.51 (-2.22), ABMD: 92.89 (+4.09), JAZZ: 191.90 (+1.24), TEVA: 71.19 (+0.50), REGN: 592.40 (+11.46)
ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health
PR Newswire - Mon Aug 03, 9:33AM CDT
ConvergeHEALTH by Deloitte is announcing that the global pharmaceutical company Allergan plc is expanding its year-long research collaboration with ConvergeHEALTH by Deloitte and Intermountain Healthcare to include women's health.
AGN: 336.64 (+5.64)
What to Watch Thursday -- Trump, Bush, Allergan Earnings, Jobless Claims
at The Street - Wed Aug 05, 7:15PM CDT
On Thursday August 6, TheStreet will be covering the first Republican Presidential debates, earnings from drug manufacturer Allergan and media company Viacom, and jobless claims.
AGN: 336.64 (+5.64), PBR: 6.32 (-0.13), MNST: 154.00 (+2.28), DUK: 73.98 (+0.06), LGF: 37.42 (-1.36), KYTH: 74.72 (+0.17), TEVA: 71.19 (+0.50), VIAB: 51.41 (-4.19)
Sucampo hits high on EPS
at Investor's Business Daily - Wed Aug 05, 5:43PM CDT
The specialty drugmaker's Q2 EPS was 21 cents up from 4 cents a year ago, beating views by 6 cents. Revenue grew 45% to $34.9 mil, above views. Sucampo (SCMP) raised its full-year EPS guidance to 65-75 cents, above analysts' views for 62 cents. But a...
AGN: 336.64 (+5.64), SCMP: 22.24 (+0.66), CVS: 111.20 (+1.24)
Third Point buys stake in Baxter, wants to help pick new CEO
AP - Wed Aug 05, 3:37PM CDT
NEW YORK (AP) — Hedge fund Third Point has become the biggest shareholder in Baxter International and wants to help choose the medical products maker's next CEO.
AGN: 336.64 (+5.64), BAX: 42.13 (+1.82), AMGN: 176.44 (+1.64), DOW: 47.13 (+0.44)
FDA Approves 28 Additional Styles Of Allergan's Natrelle® 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants
PR Newswire - Wed Aug 05, 3:26PM CDT
Allergan, plc. (NYSE: AGN) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market 28 additional styles of Natrelle® 410 silicone-filled breast implants, giving surgeons and patients more options to achieve desired outcomes. The FDA approved extra-full projection styles (X), along with additional low projection, low height styles (L) from the Natrelle® 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implant line, for use in breast reconstruction, augmentation and revision surgery.
AGN: 336.64 (+5.64)
Allergan (AGN) Stock Climbs Ahead of Second Quarter Results
at The Street - Wed Aug 05, 2:59PM CDT
Allergan (AGN) shares are rising ahead of the release of its second quarter financial results tomorrow morning before the opening bell.
AGN: 336.64 (+5.64)
What Company Will Be Fastest Growing Big-Cap Biotech?
at Investor's Business Daily - Wed Aug 05, 1:58PM CDT
While drugs for treating and curing hepatitis C have made one biotech company the envy of the industry, another biotech -- Celgene -- is poised to break ahead of its peer pack over the next few years. Celgene's (CELG) sales and profit growth is seen...
AGN: 336.64 (+5.64), BIIB: 335.41 (+5.03), GEVA: 238.60 (+2.80), PCYC: 261.25 (+1.70), GILD: 118.66 (-0.21), AZN: 34.54 (+0.20), ALXN: 197.94 (+0.79), RCPT: 228.97 (+0.97), AMGN: 176.44 (+1.64), ABBV: 70.30 (+0.35), JUNO: 46.67 (+0.17), CELG: 132.72 (+1.64)
Jim Cramer Is Watching Allergan's Earnings After Generics Sale to Teva
at The Street - Wed Aug 05, 1:50PM CDT
Allergan is set to report earnings on Thursday, before the markets open, and Jim Cramer is keeping a sharp eye on its results.
AGN: 336.64 (+5.64), VRX: 262.52 (+2.54)
Sucampo Stock Hits High On EPS, But CVS Nixes Drug
at Investor's Business Daily - Wed Aug 05, 11:52AM CDT
Specialty drugmaker Sucampo Pharmaceuticals (SCMP) beat Q2 expectations and raised its guidance early Wednesday, sending the stock to a new high in early trading. It pulled back later, however, possibly because word got out that its sole marketed...
AGN: 336.64 (+5.64), SCMP: 22.24 (+0.66), MYL: 54.60 (-0.07), CVS: 111.20 (+1.24)
Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023
M2 - Wed Aug 05, 10:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7x2jmw/antibacterial) has announced the addition of the "Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023" report to their offering. "Antibacterial Drugs Market (By Class - Aminoglycosides, B-Lactams, Tetracyclines, Sulfonamides, Quinolones/ Fluoroquinolones, Macrolides, Phenicols and Miscellaneous Antibacterials, and Pipeline Drugs) - 2015 - 2023 This report on antibacterial drugs market studies the current as well as future prospects of the market globally. The market for antibacterial drugs is segmented on the basis of major classes of drugs,namely,aminoglycosides,B-lactams, tetracyclines, sulfonamides, quinolones/fluoroquinolones, macrolides, phenicols and miscellaneous antibacterials. The market for each of these classes has been extensively analyzed on the basis of leading drug launch, patent expiry, drug efficacy, annual sales revenue and geography wise regulatory approval. The market size and forecast in terms of USD million for each of these classes has been provided for the period 2013 to 2023, considering 2013 and 2014 as the historical and base year respectively, while the market forecast has been provided for the period 2015 to 2023. Geographically, the antibacterial drugs market has been categorized into five regions, namely, North America, Europe, Asia Pacific, Latin America and Rest of the World (ROW). Each of these geographies have been further segmented with respect to major countries; where North America is segmented in U.S. and Canada, Europe is segmented in U.K., Germany and rest of Europe, Asia Pacific is segmented in China, Japan and rest of Asia Pacific, and Latin America is segmented in Brazil and rest of Latin America. Companies Mentioned - AstraZeneca plc - Allergan plc (Actavis Plc) - Bayer AG - Bristol-Myers Squibb Company - Eli Lilly and Company - GlaxoSmithKline plc - Johnson & Johnson - Merck & Co., Inc. - Novartis AG - Pfizer, Inc. - Sanofi Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Antibacterial Drugs Market Revenue, by Class, 2013 - 2023 (USD Million) Chapter 5 Global Antibacterial Drug Pipeline Analysis Chapter 6 Global Antibacterial Drugs Market Revenue, by Geography, 2013 - 2023 (USD Million) Chapter 7 Recommendations Chapter 8 Company Profiles For more information visit http://www.researchandmarkets.com/research/7x...ibacterial
AGN: 336.64 (+5.64), JNJ: 100.52 (+0.72), PFE: 35.82 (-0.29), MRK: 59.10 (+0.40), AZN: 34.54 (+0.20), LLY: 84.73 (+0.68), GSK: 44.17 (+0.72), BMY: 65.06 (+0.22), NVS: 103.25 (-0.32)
Sustained Release Ocular Drug Delivery Systems, 2015 - 2025
M2 - Wed Aug 05, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g2gzr3/sustained_release) has announced the addition of the "Sustained Release Ocular Drug Delivery Systems, 2015 - 2025 (2nd edition)" report to their offering. The Sustained Release Ocular Drug Delivery Systems, 2015 - 2025 (2nd edition)' report provides an extensive study of the emerging market of implants and particulate drug delivery systems (DDS) for ophthalmic diseases. The focus of this study is on commercial implants and those under development, their applications and the likely mid-term and long-term evolution. It is widely anticipated that such drug delivery systems have tremendous potential as they provide improved retention time compared to topical applications and offer convenience over regular intravitreal injections, mainly for posterior eye diseases. The report covers various aspects such as technological progress, product pipeline, target indications, industry and academic research programs to assess new evolving opportunities. We have provided a competitive spider web analysis to compare different implants based on technical parameters (drug elution rate, amount of drug delivered, life of implant etc.) and their likely user friendliness. Our opinion and insights, presented in this study, were influenced by the discussions that we conducted with different ophthalmic implant developers in this industry. The base year for the report is 2014. The report provides market forecasts for the following two time horizons: 2015 - 2020 and 2020 - 2025. In addition to the above, we have also provided our own independent perspective on the key drivers behind the growth of this market, likely challenges and potential threats. The research, analysis and insights presented in this report include the sales potential of various marketed and late stage pipeline ocular sustained drug delivery systemsbased on the current expected launch timelines, adoption rates and the estimated end-use price points.The figures mentioned in this report are in USD, unless otherwise specified. Highlights: - More than 25 companies are currently working on developing sustained release drug delivery systems for the treatment of ocular indications. Examples of some key players include pSivida, Allergan, Ocular Therapeutix, Neurotech Pharmaceuticals, Icon BioScience and GrayBug. - Vitrasert, launched in 1996, was the first ocular implant. It was, however, taken off the market in 2013. Only three more implants have received regulatory approval since 1996; these are Retisert, Ozurdex and Iluvien. - Majority of the systems (52%) are in preclinical stage of development. Over 10 systems are currently undergoing late stage clinical trial studies. Once approved, these inserts are likely to provide a major impetus to the overall market. - DME and Uveitis will provide the much needed boost to the sustained release ocular drug delivery systems market in the short-term. In the mid to long term, the growth will be fostered by launch of sustained release systems for glaucoma and AMD. In fact, more than 15 sustained release formulations are under development for the treatment of glaucoma. - Interest of venture capital firms, licensing/ partnership opportunities will continue to act as key growth drivers of this market. During our research, we identified several instances where venture capitalists and other strategic investors have actively supported the research efforts. - The overall market is likely to be more than USD 6.5 billion in the coming decade. The opportunity could be much higher in the outer years, especially driven by the regulatory approval of implants for delivery of biologics. Key Topics Covered: 1. Preface 2. Executive Summary 3. Introduction 4. Market Overview 5. Product Profiles and Sales Forecast 6. Company Profiles 7. Venture Capital Support 8. Recent Partnerships 9. SWOT Analysis 10. Interview Transcripts 11. Conclusion 12. Appendix 1: Tabulated Data 13. Appendix 2: List Of Companies Companies Mentioned - Partial List of Companies - 3i Plc - AbbVie - Abell Foundation - Aciont, Inc. - Actavis Plc - Aerie Pharmaceutical - Ain Shams University, Cairo, Egypt - Alcon - Alimera Sciences - Allergan - Alliance Medical Products Inc - Alpha Associates - Amgen Inc. - Amorphex Therapeutics - Apax Partners - Ascension Health Ventures - Atlas Venture - Auritec Pharmaceuticals - Avida Group - Bausch & Lomb - Baxter Venture - Bayer Healthcare - BCN Peptides - Ben Venue Laboratories - BioLight Israeli Life Sciences Investments Ltd. - Brandon Biosciences - Brecon Pharmaceuticals Ltd - Brown Advisory For more information visit http://www.researchandmarkets.com/research/g2...ed_release
AGN: 336.64 (+5.64), ALIM: 4.69 (-0.10), AMGN: 176.44 (+1.64), OCUL: 23.43 (+1.38)
Ironwood and Allergan Enter Agreement to Co-Promote VIBERZI for Irritable Bowel Syndrome with Diarrhea (IBS-D) in the U.S.
Business Wire - Wed Aug 05, 8:25AM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today an agreement with Allergan plc for the U.S. co-promotion of VIBERZI(TM) (eluxadoline), Allergan's new treatment for adults suffering from irritable bowel syndrome with diarrhea (IBS-D). This arrangement is separate from and complementary to the companies' ongoing co-development and co-commercialization of LINZESS(R) (linaclotide) for the treatment of adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).
AGN: 336.64 (+5.64), IRWD: 10.72 (+0.10)
Pharmaceuticals Partnerships, Licensing, Investments and M&A Deals and Trends for 2014
M2 - Wed Aug 05, 7:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qkmkxx/partnerships) has announced the addition of the "Partnerships, Licensing, Investments and M&A Deals and Trends for 2014 in Pharmaceuticals" report to their offering. Partnerships, Licensing, Investments and M&A Deals and Trends for 2014 in Pharmaceuticals report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in 2014. The report portrays detailed comparative data on the number of deals and their value in the last five years, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry. Major Highlights - Actavis Acquires Allergan for USD70.5 Billion - Medtronic Acquires Covidien for USD49.9 Billion - Actavis Completes Acquisition of Forest Labs for USD28 Billion - Sigma-Aldrich Receives Antitrust Approval for its Acquisition by Merck for USD17 Billion - Novartis Acquires Cancer Drugs Business of GlaxoSmithKline - Bayer Acquires Consumer Healthcare Business of Merck for USD14.2 Billion - GlaxoSmithKline Acquires Consumer Healthcare Pharma Business of Novartis - Merck Acquires Cubist Pharma for USD9.5 Billion - McKesson Completes Acquisition Of Celesio For US$8.49 Billion - Roche Completes Tender Offer to Acquire InterMune for USD8.3 Billion Key Topics Covered: 1 Tables & Figures 2 Pharmaceutical & Healthcare, Global, Deals Summary 3 Pharmaceuticals & Healthcare, Global, Top Deal Makers, 2014 4 Pharmaceuticals & Healthcare, Global, Deal Summary, by Type 5 Pharmaceuticals & Healthcare, Global, Deal Summary, By Market 6 Pharmaceuticals & Healthcare, Deal Summary, By Geography 7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 8 Further Information For more information visit http://www.researchandmarkets.com/research/qk...rtnerships
AGN: 336.64 (+5.64), MDT: 78.67 (+0.90), MRK: 59.10 (+0.40), GSK: 44.17 (+0.72), NVS: 103.25 (-0.32)
Allergan and KYTHERA Announce That Pending Transaction Will Now be for All-Cash Consideration
GlobeNewswire - Wed Aug 05, 7:00AM CDT
Allergan plc (NYSE:AGN) and KYTHERA Biopharmaceuticals, Inc. (NASDAQ:KYTH) today announced that they have amended and restated their merger agreement with respect to Allergan's pending acquisition of KYTHERA to provide for all-cash consideration to KYTHERA's stockholders. The agreement amends and restates the original merger agreement entered into by the parties on June 17, 2015, as amended on July 1, 2015.
AGN: 336.64 (+5.64), KYTH: 74.72 (+0.17)
Allergan and KYTHERA Announce that Pending Transaction will now be for All-Cash Consideration
PR Newswire - Wed Aug 05, 7:00AM CDT
Allergan plc (NYSE: AGN) and KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that they have amended and restated their merger agreement with respect to Allergan's pending acquisition of KYTHERA to provide for all-cash consideration to KYTHERA's stockholders. The agreement amends and restates the original merger agreement entered into by the parties on June 17, 2015, as amended on July 1, 2015.
AGN: 336.64 (+5.64), KYTH: 74.72 (+0.17)
Top Mutual Funds Pile In Celgene Other Leading Stocks
at Investor's Business Daily - Tue Aug 04, 5:51PM CDT
IBD's new buys list showed the country's leading stock mutual funds the past three months have continued to gobble up top-rated medical stocks, such as Allergan (AGN), Celgene (CELG), Regeneron Pharmaceuticals (REGN), Molina Healthcare (MOH) and...
ACHC: 82.97 (+5.08), LAD: 119.80 (+0.81), MNST: 154.00 (+2.28), NKE: 116.75 (+0.98), SKX: 160.29 (+6.39), ORLY: 244.17 (+0.80), VFC: 76.72 (+0.49), GOOG: 643.78 (+14.53), MOH: 77.24 (+1.84), CELG: 132.72 (+1.64), SBUX: 59.01 (+0.31), AGN: 336.64 (+5.64), TSS: 47.54 (+0.47), PZZA: 71.45 (-4.16), HAWK: 45.45 (-0.14), ULTA: 167.01 (+1.94), REGN: 592.40 (+11.46)
Akorn's
at Investor's Business Daily - Tue Aug 04, 5:41PM CDT
Akorn's (AKRX) Hi-Tech Pharmacal lost after when the U.S. Court of Appeals for the Federal Circuit ruled that Akorn had infringed on 3 Allergan (AGN) patents for its Lumigan topical glaucoma treatment, Reuters reported. Akorn shares fell 0.7% to...
AGN: 336.64 (+5.64), AKRX: 45.12 (-0.74)
Will Allergan's (AGN) Earnings Streak Continue in 2Q? - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Aug 04, 5:02PM CDT
Allergan's (AGN) top as well as bottom line should continue to be driven by the acquisition of Botox-maker Allergan Inc. as well as other acquisitions.
BDSI: 7.81 (+0.17), DVAX: 29.73 (-0.48), AGN: 336.64 (+5.64), TEVA: 71.19 (+0.50)
Asia, Europe, and South America Anti-aging Market - Industry Analysis 2014 - 2020
M2 - Tue Aug 04, 8:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lsx3v/asia_europe_and) has announced the addition of the "Asia, Europe, and South America Anti-aging Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020" report to their offering. The anti-wrinkle products segment was valued at USD 8,088.3 million in 2013 in Asia The dominance of this segment was primarily due to increasing adoption of anti-wrinkle products among the population. The anti-aging products market in Japan is growing swiftly owing to reasonable costs and rising awareness about the availability of aesthetic products. According to the International Society of Aesthetic Plastic Surgeons (ISAPS), a total of 146,150 Botox injection procedures were registered in Japan in 2010. The number further increased to 208,313 in 2011. Considering all the above mentioned factors, Japan was leading the overall anti-aging products market in Asia in terms of revenue in 2013. While on the other hand, China is expected to show significant growth in the anti-aging products market during the forecast period. Factors such as anticipated rise in the aging population coupled with rising awareness about commercially available anti-aging products are primarily driving the growth of the market in China. The anti-aging services market is growing rapidly in Europe owing to steady recovery from the economic crisis, and consequently, rising disposable income and increasing demand. Italy was a leader in the anti-aging services market in the overall Europe in 2013 due to higher demand for breast augmentation and hair restoration treatments. While on the other hand, Spain anti-aging services market is expected to record highest growth during the forecast period. Adoption of sclerotherapy is anticipated to primarily boost the growth of the Spain anti-aging treatment services market owing to the increasing prevalence of varicose vein due to aging and obesity. The growth of the geriatric population coupled with rise in obesity are some of the other factors driving the growth of sclerotherapy services segment in the country. Brazil dominates the aesthetic procedures industry among South American countries. Brazil registered 1,447,213 aesthetic procedures in 2011. Affordable rates, availability of advanced techniques and a well-defined regulatory infrastructure are the prime drivers for the growth of the aesthetic industry in Brazil. As a result, people around the world travel to Brazil for aesthetic treatment. Thus, increasing demand for aesthetic procedures in the country is observed that would boost the growth of aesthetic devices in Brazil. Similarly, adoption of laser treatment and radiofrequency treatments is observed to be higher in Brazil owing to the safety and efficacy of these treatments. Therefore, in 2013, the laser aesthetic and radiofrequency devices segments accounted for the largest market of USD 59.0 million and USD 19.2 million, respectively. Some of the key players operating in the anti-aging market include Allergan, Inc., Alma Laser Ltd., Beiersdorf AG, Coty, Inc., Cynosure, Inc., L'Or?al SA, Solta Medical, Inc. (Valeant Pharmaceutical International, Inc.), and PhotoMedex, Inc. For more information visit http://www.researchandmarkets.com/research/4l...europe_and
AGN: 336.64 (+5.64), CYNO: 39.67 (+0.59), COTY: 28.32 (+0.83)
5 Top Medical Stocks Reporting Earnings This Week
at Investor's Business Daily - Mon Aug 03, 12:05PM CDT
Before Wall Street escapes for summer vacation, makers of drugs and medical devices are greeting August with a frantic week of earnings reports. Here are five of the leading stocks reporting this week: On Tuesday morning, big biotech Regeneron...
AGN: 336.64 (+5.64), MNK: 104.51 (-2.22), ABMD: 92.89 (+4.09), JAZZ: 191.90 (+1.24), TEVA: 71.19 (+0.50), REGN: 592.40 (+11.46)
ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health
PR Newswire - Mon Aug 03, 9:33AM CDT
ConvergeHEALTH by Deloitte is announcing that the global pharmaceutical company Allergan plc is expanding its year-long research collaboration with ConvergeHEALTH by Deloitte and Intermountain Healthcare to include women's health.
AGN: 336.64 (+5.64)
